Renin-Angiotensin System
Wegovy may reduce need for antihypertensive, lipid-lowering therapies
Adults receiving semaglutide for the treatment of obesity were more likely to have antihypertensive or lipid-lowering therapy tapered or discontinued than those receiving placebo, according to data from the STEP trials.
Choice to halt RAS therapy before major surgery can be left to patient, physician
Discontinuation of renin-angiotensin system inhibitor therapy before major noncardiac surgery did not appear to affect postoperative outcomes vs. treatment continuation, a speaker reported.
Renin-angiotensin system blockade beneficial for Black and non-Black patients with HFrEF
Renin-angiotensin system blockade conferred similar mortality benefits for Black vs. non-Black patients with HF, and despite less benefit for hospitalization for Black patients, absolute benefit was comparable, researchers reported.
Aldosterone: The hidden hormone linking hypertension and obesity, and a potential target
An op-ed published in February by Tom Frieden, MD, MPH, former director of the CDC, described hypertension as “the deadliest but most neglected and widespread pandemic of our time” — and he’s right.
Two post-approval outcome trials of anti-hyperkalemia drug stopped for logistical reasons
AstraZeneca announced that two post-approval randomized heart- and kidney-related outcome studies of its anti-hyperkalemia drug have been stopped due to slow enrollment and low event rates.
Intensive medication optimization cost-effective in patients hospitalized with HFrEF
PHILADELPHIA — An intensive medication optimization program for patients hospitalized with HF with reduced ejection fraction would be cost-effective, researchers reported at the American Heart Association Scientific Sessions.
Patients with hyperkalemia less likely to receive RAAS inhibitors, have worse HF outcomes
Chinese adults with HF and dyskalemia were less likely to receive renin-angiotensin-aldosterone system inhibitors than patients with normokalemia, and those with hyperkalemia were more likely to experience worsening HF or CV death.
Diuretic with renin-angiotensin system inhibitor slows CKD progression
Adding a diuretic to renin-angiotensin system inhibitor therapy lowered the risk for disease progression in patients with chronic kidney disease compared with using a calcium channel blocker, according to study data.
Early, rapid uptitration of HF therapies after discharge reduces death, readmission risk
Rapid uptitration of medical therapy early after hospitalization for acute HF improves prognosis independent of left ventricular ejection fraction, according to a prespecified analysis of the STRONG-HF trial.
‘Dips’ in eGFR after sacubitril/valsartan transition should not stall HF therapy
Declines in renal function observed during transition from a renin-angiotensin system inhibitor to sacubitril/valsartan for HF are variable but usually small and partially recoverable for most patients, researchers reported.